Sept 14: After announcing Tuesday that its CRF1 antagonist, crinecerfont, met the primary efficacy endpoint in the Phase III CAHtalyst Adult Study for classic congenital adrenal hyperplasia, Neurocrine Biosciences reported good news on the neuro front
Follow these steps exactly for optimal results
No forum math, no guesswork
Don't forget the essentials The **BPC-157 + TB-500 10mg** combo delivers in a single vial the two most extensively studied tissue regeneration peptides in musculoskeletal research: **5 mg of BPC-157** (Body Protection Compound-157, a 15-amino-acid pentadecapeptide derived from human gastric juice, isolated by Predrag Sikiric's team at Zagreb from the 1990s) paired with **5 mg of TB-500** (active fragment of thymosin beta-4 described by Allan Goldstein in 1981, 44-residue ubiquitous regeneration peptide)
The choice often comes down to personal preference and tolerance for injections
Venous hypertension and arterial hypotension and tachycardia, rapidly presented, which were collectively attenuated or counteracted, emphasize BPC 157s therapeutic effects (Vukojevic et al., 2018
